Open | $31.270 |
Close | $31.030 |
Volume / Avg. | 778.815K / 1.146M |
Day Range | 30.440 - 31.910 |
52 Wk Range | 9.440 - 35.613 |
Market Cap | $1.545B |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 62 |
Short Interest | 17.73% |
Days to Cover | 1.98 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of 4D Molecular Therapeutics (NASDAQ: FDMT) through any online brokerage.
Other companies in 4D Molecular Therapeutics’s space includes: Immunome (NASDAQ:IMNM), 89bio (NASDAQ:ETNB), Gyre Therapeutics (NASDAQ:GYRE), Prothena Corp (NASDAQ:PRTA) and Xencor (NASDAQ:XNCR).
The latest price target for 4D Molecular Therapeutics (NASDAQ: FDMT) was reported by HC Wainwright & Co. on Friday, March 1, 2024. The analyst firm set a price target for 36.00 expecting FDMT to rise to within 12 months (a possible 16.02% upside). 16 analyst firms have reported ratings in the last year.
The stock price for 4D Molecular Therapeutics (NASDAQ: FDMT) is $31.03 last updated March 18, 2024 at 4:16 PM EDT.
There are no upcoming dividends for 4D Molecular Therapeutics.
4D Molecular Therapeutics’s Q1 earnings are confirmed for Wednesday, May 8, 2024.
There is no upcoming split for 4D Molecular Therapeutics.
4D Molecular Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.